1. Home
  2. RBB vs LXEO Comparison

RBB vs LXEO Comparison

Compare RBB & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RBB Bancorp

RBB

RBB Bancorp

HOLD

Current Price

$26.56

Market Cap

451.0M

Sector

Finance

ML Signal

HOLD

Logo Lexeo Therapeutics Inc.

LXEO

Lexeo Therapeutics Inc.

HOLD

Current Price

$4.47

Market Cap

396.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RBB
LXEO
Founded
2008
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
451.0M
396.5M
IPO Year
2017
2023

Fundamental Metrics

Financial Performance
Metric
RBB
LXEO
Price
$26.56
$4.47
Analyst Decision
Hold
Strong Buy
Analyst Count
2
9
Target Price
$22.00
$18.44
AVG Volume (30 Days)
203.3K
972.8K
Earning Date
04-20-2026
05-06-2026
Dividend Yield
2.68%
N/A
EPS Growth
24.49
39.81
EPS
0.66
N/A
Revenue
$5,167,000.00
$654,000.00
Revenue This Year
$20.50
N/A
Revenue Next Year
$6.90
N/A
P/E Ratio
$39.82
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.74
$4.03
52 Week High
$28.24
$10.99

Technical Indicators

Market Signals
Indicator
RBB
LXEO
Relative Strength Index (RSI) 50.36 45.79
Support Level $20.11 $4.30
Resistance Level $28.22 $5.36
Average True Range (ATR) 0.80 0.35
MACD -0.20 -0.00
Stochastic Oscillator 34.06 18.37

Price Performance

Historical Comparison
RBB
LXEO

About RBB RBB Bancorp

RBB Bancorp operates as a bank holding company. It provides various banking products and services such as checking, savings, money market accounts, and certificates of deposits. Its Specific services include remote deposit, E-banking, mobile banking, commercial and investor real estate loans, business loans and lines of credit, Small Business Administration (SBA) 7A and 504 loans, mortgage loans, trade finance, and a full range of depository accounts. It generates its revenue from interest received on loans and leases and, to a lesser extent, from interest received on investment securities and derives income from noninterest sources, such as fees received in connection with various lending and deposit services, loan servicing, gain on sales of loans, and wealth management services.

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Share on Social Networks: